Delving into the Latest Updates on Ingavirin with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

IMIDAZOLYL ETHANAMIDE PENTANDIOIC ACID, Vitaglutam

+ [2]

Target-

Mechanism

Apoptosis inhibitors, Granulocytes stimulants, Haematopoiesis stimulants

+ [1]

Therapeutic Areas

Infectious DiseasesHemic and Lymphatic DiseasesRespiratory Diseases

Active Indication

Virus DiseasesInfluenza, HumanNeutropenia

Inactive Indication

Acute Radiation SyndromeAcute respiratory infectionsBone marrow depression+ [6]

Originator Organization

Valenta Pharmaceuticals JSC

Active Organization

Valenta Pharmaceuticals JSC

Inactive Organization

Myelo Therapeutics GmbHBausch Health Americas, Inc.

Drug Highest PhaseApproved

First Approval Date

RU (01 Jan 2009),

Influenza, HumanNeutropenia

Regulation-

Login to view timeline

Structure

Molecular FormulaC10H15N3O3

InChIKeyKZIMLUFVKJLCCH-UHFFFAOYSA-N

CAS Registry219694-63-0

The primary objective of this study is to investigate the efficacy of Ingavirin®, 90 mg capsules in achieving clinical improvement of novel coronavirus disease (COVID-19) symptoms. A secondary goal of this study is to evaluate the safety of Ingavirin®, 90 mg capsules in patients with COVID-19 infection.

Start Date06 Oct 2021

Sponsor / Collaborator

Valenta Pharmaceuticals JSC

NCT05269290 / CompletedPhase 3

A Multicenter, Double-blind, Randomized, Placebo-controlled Study of the Efficacy and Safety of Ingavirin®, Syrup, 30 mg/5 ml, in Children Aged 6 Months to 2 Years With Influenza and Other Acute Respiratory Viral Infections Against Standard Therapy

The study is planned to evaluate the therapeutic efficacy and safety of Ingavirin®, syrup, 30 mg/5 ml, in the treatment of influenza or other acute respiratory infections in children from 6 months to 2 years compared with placebo.

Start Date23 Sep 2021

Sponsor / Collaborator

Valenta Pharmaceuticals JSC

100 Clinical Results associated with Ingavirin

Login to view more data

100 Translational Medicine associated with Ingavirin

Login to view more data

100 Patents (Medical) associated with Ingavirin

Login to view more data

36

Literatures (Medical) associated with Ingavirin

01 Dec 2023·Molecular Diversity

Insight into the Hantaan virus RNA-dependent RNA polymerase inhibition using in-silico approaches

Article

Author: Sharaf, Mohamed ; Abdalla, Mohnad ; Badshah, Syed Lal ; Faisal, Shah

The Hantaan virus (HTN) is a member of the hantaviridae family. It is a segmented type, negative-strand virus (sNSVs). It causes hemorrhagic fever with renal syndrome, which includes fever, vascular hemorrhage, and renal failure. This illness is one of the most serious hemorrhagic diseases in the world, and it is a major public health concern due to its high mortality rate. The Hantaan virus RNA-dependent RNA polymerase complex (RdRp) is involved in viral RNA transcription and replication for the survival and transmission of this virus. Therefore, it is a primary target for antiviral drug development. Interference with the endonucleolytic "cap-snatching" reaction by the HTN virus RdRp endonuclease domain is a particularly appealing approach for drug discovery against this virus. This RdRp endonuclease domain of the HTN virus has a metal-dependent catalytic activity. We targeted this metal-dependent enzymatic activity to identify inhibitors that can bind and disrupt this endonuclease enzyme activity using in-silico approaches i.e., molecular docking, molecular dynamics simulation, predicted absorption, distribution, metabolism, excretion, toxicity (ADMET) and drug-likeness studies. The docking studies showed that peramivir, and ingavirin compounds can effectively bind with the manganese ions and engage with other active site residues of this protein. Molecular simulations also showed stable binding of these ligands with the active site of HTN RdRp. Simulation analysis showed that they were in constant contact with the active site manganese ions and amino acid residues of the HTN virus endonuclease domain. This study will help in better understanding the HTN and related viruses.

01 Jan 2020·Ceska a Slovenska farmacie : casopis Ceske farmaceuticke spolecnosti a Slovenske farmaceuticke spolecnosti

Ingavirin might be a promising agent to combat Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2).

Article

Author: Padrtova, Tereza ; Kovac, Gustav ; Hudecova, Lucia ; Malík, Ivan

The Severe Acute Respiratory Coronavirus 2 (SARS--CoV-2) and Coronavirus Disease-19 (COVID-19) pandemic, caused by the virus, have changed the world in just half a year. Lack of effective treatment, coupled with etiology of COVID-19, has resulted in more than 500,000 confirmed deaths at the time of writing, and the global economy is at an unseen unprecedented low level with unknown near- and long-term consequences. Ingavirin has been considered a non-toxic broad-spectrum antiviral with a complex mechanism of action. The molecule was originally designed for the prophylaxis and treatment of flu caused by both Influenza A and B viruses and for the treatment of viral causes of acute respiratory illness. The article hypothesized that the efficiency of given 1H-imidazol-4-yl heterocyclic scaffold-containing compound against SARS-CoV-2 might be connected with its ability to interfere with specific heterogeneous nuclear ribonucleoproteins (A1, for example). These specific cellular RNA-binding proteins showed affinity to Severe Acute Respiratory Coronavirus (SARS-CoV) nucleocapsid (N) protein, which shared high homology with the N protein of SARS-CoV-2 and the fact was expressed by a sequence identity of 90.52%. Impairing of the interactions between nuclear ribonucleoproteins and nucleocapsid (N) protein of SARS-CoV-2 might result in the inhibition of a viral replication cycle. Additional immunomodulating properties of ingavirin could be favorable for induction of adaptive immunity of host cells.

01 Jan 2013·Terapevticheskii arkhivQ4 · MEDICINE

[Current principles in the chemoprophylaxis of acute respiratory viral infections].

Q4 · MEDICINE

ArticleOA

Author: Liapina, E P ; Shul'diakov, A A ; Kuznetsov, V I

AIMTo evaluate the preventive efficacy of the Russian antiviral drug ingavirin (vitaglutam) in the epidemiological foci with the peak incidence of acute respiratory viral infections (ARVI).SUBJECTS AND METHODSFour hundred men and women aged 18 to 65 years from the epidemic foci of ARVI who had been in close daily contact with the patients whose diagnosis was verified by laboratory tests were examined. Two hundred persons received prophylaxis with ingavirin (a 90-mg oral capsule once daily for 7 days) and 200 took placebo according to the same scheme. The efficiency index and coefficient were calculated and the relative risk of the disease was estimated to evaluate the efficiency of ARVI prevention. A pharmacoeconomic analysis was made.RESULTSThere is evidence that the administration of 90-mg ingavirin capsules (OAO "Valenta Farm", Russia) caused a reduction in morbidity rates among those who had been in contact by 63% and in the risk of ARVI by 2.7 times. There was a reduction in the duration of fever by one day and a milder course of respiratory disease in the ingavirin-treated contact persons who developed ARVI.CONCLUSIONIngavirin meets all requirements for current drugs for the nonspecific prevention of ARVI at the peak of its incidence. It has a pronounced protective effect and broad-spectrum activity, low toxicity and high safety, which allows it to be recommended for the emergency intrafocal prevention at the peak of the incidence of influenza and ARVI in adults.

100 Deals associated with Ingavirin

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	J05AX	DB11944

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Virus Diseases	RU	Valenta Pharmaceuticals JSC	17 Jul 2014
Influenza, Human	RU	-	01 Jan 2009
Neutropenia	RU	-	01 Jan 2009

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
COVID-19	Phase 3	RU	Valenta Pharmaceuticals JSC	06 Oct 2021
Bone marrow depression	Phase 3	DE	Myelo Therapeutics GmbH	01 Mar 2016
Breast Cancer	Phase 3	DE	Myelo Therapeutics GmbH	01 Mar 2016
Cervical Intraepithelial Neoplasia	Phase 3	DE	Myelo Therapeutics GmbH	01 Mar 2016
Chemotherapy-Induced Febrile Neutropenia	Phase 3	DE	Myelo Therapeutics GmbH	01 Mar 2016
Acute respiratory infections	Phase 3	RU	Valenta Pharmaceuticals JSC	03 Oct 2010
Common Cold	Phase 3	RU	Valenta Pharmaceuticals JSC	03 Oct 2010
Common Cold	Phase 3	RU	Bausch Health Americas, Inc.	03 Oct 2010
Viral respiratory infection	Phase 3	RU	Valenta Pharmaceuticals JSC	03 Oct 2010
Influenza, Human	Discovery	RU	Valenta Pharmaceuticals JSC	03 Oct 2010

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASCO2020	Phase 2	Chemotherapy-induced myelosuppression	-	IEPA	(ycyspzpeck) = reduced yysrtecxod (qecdwohrmo ) View more	-	25 May 2020
				IEPA (Control)
NCT02692742 (ASCO2019) Manual	Phase 2	Breast Cancer	130	Myelo001	aiobnbjqgb(kemaxxshdg) = jikfrbmphc gigpeyrnpa (mtzzlkyplz, 12.6 - 14.5) View more	Positive	31 May 2019
				placebo	aiobnbjqgb(kemaxxshdg) = cngusljumr gigpeyrnpa (mtzzlkyplz, 13.0 - 14.9) View more